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in the United States have done any relevant clinical trials.
Tumor Cells in Peripheral Blood
In 2004, Cristofanilli, Hayes, and their colleagues reported that the circulating tumor cell level in patients with metastatic breast cancer about to start a new treatment is an independent predictor of progression-free and overall survival ( see News, Vol. 96, No. 14, p. 1055 , " Trial Results Boost Circulating Tumor Cell Field " ) .
" Measurement of [circulating tumor cells] in blood is not just another measure of tumor load but more prognostic than just measuring single metastatic sites or a tumor marker, " Cristofanilli said. " It tells you more about the biology of the disease, and it leads you to consider more personalized treatment. " He added that the persistence of circulating tumor cells 3 -4 weeks after initiation of therapy predicted the clinical effect of treatment before standard imaging modalities, suggesting that measuring circulating tumor cells could be valuable in halting futile therapy sooner rather than later. An international study testing the clinical signifi cance of circulating tumor cells in blood in patients with metastatic breast cancer is under consideration. Different uses of current therapies, such as use of bisphosphonates, may also be tested.
Tumor Cell Dormancy?
The Late this summer, their pooled analysis of more than 4,500 breast cancer patients, which was published in the August 25 New England Journal of Medicine, concluded that " the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer is associated with a poor prognosis. "
" The old view is that metastases are a late development in cancer, " Pantel said in an interview during the September Symposium on Minimal Residual Cancer in San Francisco, of which he was a co-chair. " But our work and the gene expression analyses that have been done in breast and other cancers indicate that even small tumors can spread. And those that have a tendency to spread may do so very early -most likely before detection. " Explained Massimo Cristofanilli, M.D., associate professor of breast medical oncology at the University of Texas M. D. Anderson Cancer Center and symposium co-chair: " Most large studies show that for patients at high risk -4+ lymph nodes -we are not improving survival very much, even with the most aggressive chemotherapy such as taxotere. The European data show that bone marrow may contain dormant tumor cells that are not attacked by chemotherapy in common use. New therapeutic strategies are necessary to specifi cally address this microscopic disease. "
Pantel said that his group has found tumor cells in the blood months after a primary breast tumor has been removed. They believe these cells must originate from a metastatic process because cells stimulate the immune system may be worth investigating. " Dormancy seems to be a fundamental biologic process but poorly investigated, " Pantel said. " What regulates it? " Some see cancer stem cells, or progenitor or founder cells, that have selfrenewal capabilities and permanent survival abilities as key players. Such cells may remain when the rest of the tumor -composed of terminally differentiated cells -shrinks as a result of treatment, Hayes suggested. On the other hand, Uhr sees the situation as a steady state between apoptotic circulating tumor cells and replenishment of them. " We need to fi nd the mechanism that keeps this population from expanding, " he said. " It could lead to new therapies. "
Researchers Exploring Implications of Minimal Residual Cancer

Rare Event Technologies
Underlying and helping to ensure the validity of these concepts are advances in technology. " This fi eld is at the intersection of a lot of other fi elds, " Park said in an interview. " For breast cancer in particular, a series of new technology-driven approaches have hit the arena. We're trying to determine which tumors are more dangerous so that we can tailor treatments appropriately -not overtreat patients who will be cured anyway yet potentially add more treatments for diffi cult cases. Fortunately, we have a number of different treatments for breast cancer, " Park said. " Certainly, bone marrow testing tells you which tumors are worse than others, but molecular profi ling of primary tumors with expression array analysis or RT-PCR -based tests are also in use. "
Such concepts are beginning to be applied to other solid tumors. At the Seminar for Minimal Residual Cancer, for example, Wolfgang Lilleby, M.D., Ph.D., of the Norwegian Radium Hospital, reported fi nding probable prostate cancer cells in patients' bone marrow at the time of diagnosis. In a limited study, he and colleagues showed that detection of such cells after " curatively intended radiotherapy is associated with a poor outcome " and may be more sensitive than assessment of prostate-specifi c antigen levels.
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